Review Article
The Endocannabinoid System as a Therapeutic Target in Glaucoma
Table 1
Studies investigating cannabinoid-mediated neuroprotection in models of glaucoma.
| Drug | Delivery | Study | Model | Neuroprotective effect versus vehicle (treatment versus control) |
| THC | IP | Crandall et al., 2007 [68] | Episcleral vein cauterization | ~20–40% increase (10–20% loss) | THC | IV | El-Remessy et al., 2003 [69] | Intravitreal NMDA | ~9% of vehicle | CBD | IV | El-Remessy et al., 2003 [69] | Intravitreal NMDA | ~4% of vehicle | WIN 55,212-2 | Topical | Pinar-Sueiro et al., 2013 [70] | Ischemia-reperfusion (high IOP) | 9.88% increase (2.45% loss) | MetAEA | IVit | Nucci et al., 2007 [44] | Ischemia-reperfusion (high IOP) | 18.6% increase (9.4% loss) | URB597 | IP | Nucci et al., 2007 [44] | Ischemia-reperfusion (high IOP) | 15.1% increase (12.9% loss) | URB597 | IP | Slusar et al., 2013 [71] | Axotomy | 1 week, 19.5% increase (27.9% loss) 2 weeks, 22.7% increase (58.9% loss) | Celecoxib | IP | Sakai et al., 2009 [72] | Ischemia-reperfusion (high IOP) | 25.8% increase (39.1% loss) | SC-58236 | IP | Ju et al., 2003 [45] | Ischemia-reperfusion (high IOP) | Central, 28.4% increase (27.3% loss) Peripheral, 28% increase (26.8% loss) |
|
|
IP, intraperitoneal; IV, intravenous; IVit, intravitreal; study reported quantification of tunnel positive cells only.
|